GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bakhu Holdings Corp (OTCPK:BKUH) » Definitions » Debt-to-EBITDA

Bakhu Holdings (Bakhu Holdings) Debt-to-EBITDA : -182.82 (As of Jan. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bakhu Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bakhu Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $0.41 Mil. Bakhu Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $7.63 Mil. Bakhu Holdings's annualized EBITDA for the quarter that ended in Jan. 2024 was $-0.04 Mil. Bakhu Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -182.82.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bakhu Holdings's Debt-to-EBITDA or its related term are showing as below:

BKUH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.19   Med: -0.34   Max: 0
Current: -5.19

BKUH's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BKUH: -5.19

Bakhu Holdings Debt-to-EBITDA Historical Data

The historical data trend for Bakhu Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bakhu Holdings Debt-to-EBITDA Chart

Bakhu Holdings Annual Data
Trend Jul08 Jul09 Jul10 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.34 -0.28 -0.42 -0.68

Bakhu Holdings Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.54 -0.49 0.58 -1.76 -182.82

Competitive Comparison of Bakhu Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Bakhu Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bakhu Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bakhu Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bakhu Holdings's Debt-to-EBITDA falls into.



Bakhu Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bakhu Holdings's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.745 + 0) / -9.978
=-0.68

Bakhu Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.41 + 7.634) / -0.044
=-182.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Bakhu Holdings  (OTCPK:BKUH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bakhu Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bakhu Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bakhu Holdings (Bakhu Holdings) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite 130, Long Beach, CA, USA, 90831
Bakhu Holdings Corp is a development stage company engaged in the production, manufacturing, and sale of cannabis and byproducts. The company also provides cannabis-related research, teaching and education for both medical and other purposes, and all medical uses and applications of cannabis, within the Territory.
Executives
Tom Vaknin director SPYROU KYPRIANOU 16, PYGROS / LIMMASOL G4 4529
Moshe Morgenstern director MENACHEM BEGIN 88, PETAH TIKVAH/CENTRAL DISTRICT L3 49504
Geoffrey Robert Dixon 10 percent owner 16 SHOBY LANE, GRIMSTON X0 LE14 3DD
Michael Richard Hawthorne officer: Deputy CEO 20 LARKSBOROUGH AVENUE, COUNTY DOWN X0 BT23 8SU
Garcia La Sienra Garcia Juan Carlos director, officer: CFO 3 SHANEWOOD CT, THE WOODLANDS TX 77382
Sagi Rami Rozen director HOUSE NUMBER 8, 8 AGIAS TRIADAS STREET (MOUTTAGIAKA), LIMASSOL G4 4527
Cell Science Holding, Ltd. 10 percent owner PANTELI KATELARI 18A, AGIOS IOANNIS, LIMASSOL G4 3012
Mentone, Ltd. 10 percent owner 3 COPLOW CRESCENT, SYSTON, LEICESTER X0 LE7 2JE
Inter-m Traders Fz, Lle 10 percent owner 18A PENTELI KATELARI, LIMASSOL G4 3021
Thomas K Emmitt director, officer: President, CEO and Secretary ONE WORLD TRADE CENTER, SUITE 130, LONG BEACH CA 90831
Aristotle Popolizio director 206 PASSAIC AVENUE, ROSELAND NJ 07068
Evripides Drakos director 139C GLOUCESTER TERRACE, LANCASTER GATE, LONDON X0 W2 6DX
Peter Whitton director 3 COPLOW CRESCENT, SYSTON LEICESTER X0 LE7 2JE
Oz Corp 10 percent owner 24328 VERMONT AVENUE, SUITE 300, HARBOR CITY CA 90710